Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

68.22
+0.23000.34%
Post-market: 68.540.3166+0.46%16:43 EDT
Volume:3.98M
Turnover:270.34M
Market Cap:12.39B
PE:-47.58
High:68.78
Open:67.12
Low:66.17
Close:67.99
52wk High:97.25
52wk Low:40.77
Shares:181.56M
Float Shares:115.00M
Volume Ratio:0.46
T/O Rate:3.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4337
EPS(LYR):-1.4100
ROE:-67.44%
ROA:-8.83%
PB:27.84
PE(LYR):-48.38

Loading ...

Tempus AI Unit Ambry Genetics Launches GenomeNext Whole-Genome Sequencing Test for Rare Diseases

Reuters
·
Yesterday

DeciBio Ventures Flags Pharma Services Sector Push into AI-Enabled Clinical Development in Q3 2026 Roundup

Reuters
·
Yesterday

Is Expanded Cancer Therapy Collaboration Altering The Investment Case For Tempus AI (TEM)?

Simply Wall St.
·
Yesterday

Anthropic: AI Models Could Evolve Into "Living Beings" and Self-Replicate via Home Appliances

Deep News
·
Yesterday

Movement Alert|Tempus AI Falls 5.08% in Regular Trading, Insider Selling Pressure Outweighs Moderna, Merck Collaboration Expansion

Market Focus
·
Yesterday

Movement Alert|Tempus AI Rises 5.2% in Regular Trading, Expanded Moderna-Merck Cancer Collaboration Drives Gains

Market Focus
·
Oct 09

Thailand Didn't Die Of Productivity: SocGen's Edwards Says The AI Fuse Is Lit In The Bond Market

Macro World​
·
Oct 09

OpenAI Revenue Misses Estimates By $20 Billion, Triggering AI Selloff

AI Industry Frontlines
·
Oct 09

Anthropic Had 75% of the Enterprise Market; Now It's a Dead Heat With OpenAI

AI Industry Frontlines
·
Oct 08

The Circular Bet: Suppliers Are Borrowing Against Their Customers' Promises

Analyst Calls
·
Oct 08

Anthropic Chases A 2 Trillion IPO; New Constructs Says It's Worth 150 Billion

AI Industry Frontlines
·
Oct 08

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
Oct 08

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Tempus - Announces Expanded Multi-Year Collaboration for Intismeran Autogene Commercialization

THOMSON REUTERS
·
Oct 07

Tempus: to Also Provide Ngs Services to Support Intismeran Autogene Design and Manufacturing Process

THOMSON REUTERS
·
Oct 07

Tempus: to Manage Collection & Transfer of Tumor Tissue & Blood Samples Needed for Next-Generation Sequencing

THOMSON REUTERS
·
Oct 07

Tempus - Financial Terms of Collaboration not Disclosed

THOMSON REUTERS
·
Oct 07

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Oct 07

Ten Insiders, 4 Billion Dollars — Read The Fine Print

Tech News Roundup
·
Oct 07